GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Senti Biosciences Inc.
Senti Biosciences is a biotech company developing smart, programmable cell therapies. Its stock price is a venture bet on a breakthrough in synthetic biology. The stock price reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Oncology cell gene therapy
Senti Biosciences is a biotechnology company developing next-generation cell and gene therapies using gene circuit technology for cancer treatment. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market is valuing this complex and cutting-edge sector.
Broad Market Index - GURU.Markets
Senti Biosciences is a biotech company developing smart cell therapies that can be programmed to fight cancer and other diseases. As a component of the GURU.Markets index, it is at the forefront of science. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SNTI - Daily change in the company's share price Senti Biosciences Inc.
For Senti Biosciences, Inc., a cell therapy company, daily volatility reflects sensitivity to preclinical and clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Senti Biosciences, Inc. is a cell therapy company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with SNTI's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Senti Biosciences is a biotech company developing smart cell therapies. It's at the cutting edge of science. The company's shares reflect the high hopes and risks associated with breakthrough technologies, and their high volatility impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Senti Biosciences Inc.
Senti Biosciences' year-to-date performance is a story about the development of "smart" cell therapies. Its 12-month market cap depends entirely on progress in its preclinical programs, where it must prove that its gene pathways can direct cells to attack cancer more precisely and safely, marking the next step in the development of this treatment method.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
As an early-stage biotech, Senti is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its gene therapy platform. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Senti Biosciences is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Senti Biosciences Inc.
Senti Biosciences is a biotech company developing gene therapy. Being an early-stage company, its monthly valuation is based on the potential of its scientific platform. News about preclinical studies and technological breakthroughs are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Senti Biosciences develops "smart" cell and gene therapies that can be programmed like computer code. This is the cutting edge of synthetic biology. The chart below reflects the degree to which investors were willing to invest in these highly complex, yet potentially revolutionary, approaches to creating next-generation drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Senti Biosciences is a biotechnology company programming smart cell therapies. It's at the cutting edge of science. Its stock price reflects investors' faith in the potential of its sophisticated scientific platform and is unaffected by economic cycles. It's a bet on the future of genetic engineering.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Senti Biosciences Inc.
Senti Biosciences is a biotech company developing smart cell therapies using gene circuits. Its weekly stock price has been extremely volatile, driven by news about the progress of its scientific platform and early clinical trial data, reflecting the complexity and potential of its approach.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing smart cell therapies using gene circuits. Its weekly stock price has been extremely volatile, driven by news about the progress of its scientific platform and early clinical trial data, reflecting the complexity and potential of its approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Senti, a biotech company, lives in a world of its own. Its performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
SNTI - Market capitalization of the company Senti Biosciences Inc.
Senti Biosciences' market capitalization chart tells the story of a cutting-edge approach to cell therapy that uses gene circuits to create "smart" drugs. Its dynamics reflect investors' faith in the potential of this complex yet promising technology. It's a visualization of a risky bet on the next generation of cancer treatment.
SNTI - Share of the company's market capitalization Senti Biosciences Inc. within the market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing smart cell and gene therapies using gene circuits to treat cancer. Its share of its segment's market capitalization reflects the breakthrough nature of its technology. The chart below illustrates the high valuation volatility inherent in companies at the cutting edge of science.
Market capitalization of the market segment - Oncology cell gene therapy
Senti Biosciences is developing "smart" cell therapies using gene circuits to more precisely recognize and destroy cancer cells. The chart below shows the overall market capitalization of the cell therapy sector. It reflects the future direction of this field—the creation of "programmable" drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows cell programming. Senti Biosciences develops "gene blueprints" that enable the creation of "smart" cell therapies capable of making decisions within the body. Its line on the graph is a bet on the future of synthetic biology, where cells become living medicines.
Book value capitalization of the company, segment and market as a whole
SNTI - Book value capitalization of the company Senti Biosciences Inc.
Senti Biosciences' book value is derived from its scientific platform for creating "gene circuits" that enable cells to be programmed to perform complex therapeutic tasks. This represents cutting-edge scientific capital. The chart shows how the biotech company accumulates and spends vast resources to develop the next generation of "smart" cell and gene therapies.
SNTI - Share of the company's book capitalization Senti Biosciences Inc. within the market segment - Oncology cell gene therapy
Senti Biosciences is a company that programs cell and gene therapies to create smart drugs. Its assets are cutting-edge laboratories. The chart will show a minimal share in physical assets, as its value lies in its unique scientific platform.
Market segment balance sheet capitalization - Oncology cell gene therapy
Cell therapy development, as the BCap_Ges chart for biotech shows, is a capital-intensive niche. Senti Biosciences, programming cells to fight cancer, must invest in complex and expensive R&D and manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Senti Biosciences' balance sheet consists of capital and cutting-edge laboratories for the creation of "smart" cell therapies using gene circuits. Its value provides the financial and scientific foundation for programming living cells, which could become highly precise, tangible weapons against cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Senti Biosciences Inc.
Senti Biosciences is trying to "program" cells to create "smart" drugs. This is cutting-edge synthetic biology. Its book value represents R&D funding. Its market cap represents a bet that its revolutionary approach will work. The MvsBCap chart will reflect all the risks and the enormous potential of this future technology.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing smart cell therapies using gene circuits. Its valuation is based on its breakthrough scientific platform. The chart reflects investors' high expectations for the future of programmable medicine.
Market to book capitalization ratio for the market as a whole
Senti Biosciences is developing "smart" cell therapies using gene circuits to more precisely target diseases. This is cutting-edge synthetic biology. Its market valuation reflects the potential of this approach to make cell therapy safer and more effective. The graph shows the premium for next-generation technologies.
Debts of the company, segment and market as a whole
SNTI - Company debts Senti Biosciences Inc.
Senti Biosciences, a company at the forefront of synthetic biology, is using capital to develop smart, programmable cell therapies. This requires massive investments in R&D. This chart shows how the company is funding its ambitious research projects, which could lead to the creation of a new generation of drugs.
Market segment debts - Oncology cell gene therapy
Senti Biosciences is developing a new generation of cell and gene therapies using gene circuit technology for more precise treatment. This cutting-edge research requires significant investment. This chart shows how the company is funding its complex and expensive research toward the creation of smart drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Senti Biosciences Inc.
Senti Biosciences develops smart drugs based on cell therapy. This chart reflects its financial strategy in one of the most advanced fields of medicine. The high level of debt required to finance R&D means the company's future depends entirely on the success of its scientific developments and their ability to commercialize them.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Senti Biosciences is developing next-generation cell and gene therapies using gene-guided technology for more precise treatment. The chart illustrates the debt burden in the cutting-edge synthetic biology sector, providing insight into how the company's financial model is typical of pioneers working on smart drug development.
Debt to book value of all companies in the market
Senti Biosciences is developing a new generation of cell and gene therapies using gene-guided technology for cancer treatment. This chart, showing the financial climate, is critical for cutting-edge science. The availability of long-term "smart" money to finance such complex and risky developments is directly dependent on the state of the capital markets.
P/E of the company, segment and market as a whole
P/E - Senti Biosciences Inc.
This chart from Senti Biosciences, a company that programs cells to create smart drugs, shows how investors view the future of gene therapy. The high values reflect hopes that its technology will enable the creation of drugs that can precisely target and destroy cancer cells without harming healthy cells.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average price-to-earnings ratio for the cell therapy sector, where Senti Biosciences operates. The industry's valuation is based on future potential. The chart illustrates the general level of expectations and provides context for understanding how revolutionary the market considers Senti's cell "programming" technology.
P/E of the market as a whole
Senti Biosciences develops "smart" cell and gene therapies that can be programmed like computer code to perform complex functions in the body, such as targeting only cancer cells. This chart shows risk appetite in biotech. It helps understand whether the market believes in the revolutionary potential of this complex technology and how likely Senti Biosciences is to succeed in the clinic.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Senti Biosciences Inc.
Senti Biosciences is a pioneer in genetic engineering, creating "smart" cell therapies that can make decisions within the body to more precisely treat cancer. The company's valuation is a bet on this futuristic technology. This chart demonstrates analysts' confidence in the company's ability to bring its developments to the clinic and prove their effectiveness.
%20P%2FE%20Senti%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Senti-Biosciences-Inc.&v=1772513650856 "Chart of the company's future (projected) P/E Senti Biosciences Inc.")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Senti Biosciences uses synthetic biology to create "smart" cell and gene therapies that can make logical decisions to combat diseases. This chart plots its future profitability expectations, allowing one to assess how highly the market values its breakthrough gene circuit platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772513650870 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Senti Biosciences is a pioneer in genetic engineering, creating "smart" drugs for cancer treatment. It's at the cutting edge of science. This chart, reflecting investors' overall risk appetite, is vital for Senti. During periods of optimism, the market is willing to fund complex, long-term projects that have the potential to fundamentally change medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513650907 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Senti Biosciences Inc.
Senti Biosciences, Inc. uses synthetic biology to create "smart" cell and gene therapies that can make decisions within the body. Their financial position reflects significant investments in R&D. This chart shows how much they are investing in creating "gene circuits" that could revolutionize the treatment of cancer and other complex diseases.
Profit of companies in the market segment - Oncology cell gene therapy
Senti Biosciences is a biotechnology company developing "smart" cell and gene therapies that can be programmed to perform complex logical functions within the body. This represents the cutting edge of synthetic biology. This graph reflects the enormous potential in the genetic engineering sector, where the creation of "living drugs" could revolutionize medicine.
Overall market profit
Senti Biosciences is developing smart, programmable cell therapies. This is cutting-edge science, requiring massive investment. This graph, reflecting overall market sentiment, influences the flow of venture capital into the riskiest and longest-term biotech projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Senti Biosciences Inc.
Senti Biosciences is a pioneer in the field of "programming" cells to create "smart" drugs. The company uses genetic engineering to enable cells to make decisions and target only diseased tissue, such as cancerous tumors. This chart summarizes analyst forecasts, betting on the success of this futuristic technology.
%20profit%20of%20the%20company%20Senti%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Senti-Biosciences-Inc.&v=1772513651160 "Graph of future (projected) profit of the company Senti Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing next-generation cell and gene therapies using gene circuit technology. This enables the creation of "smart" drugs that can make decisions within the body. This chart shows profitability forecasts for the biotech sector, reflecting the high hopes for programmable medicine in the treatment of cancer and other diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772513651179 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Senti Biosciences is developing a new generation of cell and gene therapies using gene circuit technology. This is cutting-edge, but highly capital-intensive, science. The total return forecast, reflected in the chart, influences the overall investment climate and risk appetite, which determine the funding of such futuristic medical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513651190 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Senti Biosciences Inc.
Senti Biosciences develops "smart" cell therapies. This chart reflects the faith in its cutting-edge technology. For a company at the forefront of science, a high market value without sales demonstrates the extent to which investors believe in its ability to program cells to fight disease.
P/S market segment - Oncology cell gene therapy
Senti Biosciences, Inc. is a biotechnology company that programs cell and gene therapies to create smart drugs. This chart reflects the average revenue estimate in the biotechnology sector. It allows us to estimate the premium investors place on the potential of Senti's platform for creating drugs that can differentiate between diseased and healthy cells and act selectively.
P/S of the market as a whole
Senti Biosciences is a company at the forefront of synthetic biology, programming genetic circuits to create intelligent cell and gene therapies capable of making decisions. This represents the next step in medicine. This chart, showing the valuation of companies with real revenues, highlights the enormous expectations for technologies that could revolutionize cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Senti Biosciences Inc.
Senti Biosciences develops "smart" cell therapies that can be programmed to perform complex logical functions, such as attacking only cancer cells and ignoring healthy ones. This chart reflects investors' faith in the future of genetic engineering. The valuation is based on the potential of this platform to create safer and more effective drugs.
%20P%2FS%20Senti%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Senti-Biosciences-Inc.&v=1772513651285 "The graph of the company's future (projected) P/S Senti Biosciences Inc.")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Senti Biosciences is developing a new generation of cell and gene therapies using "gene-guided" technology, which allows drugs to act more precisely and selectively. This chart shows how the market values its breakthrough programmable platform compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772513651330 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Senti Biosciences is developing a new generation of cell and gene therapies using gene circuit technology for more precise cancer treatment. This schedule, reflecting investor appetite for breakthrough scientific platforms, is vital for Senti. Market optimism is essential for funding such complex and capital-intensive research, which has the potential to revolutionize medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513651444 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Senti Biosciences Inc.
Senti Biosciences is a biotech company developing "smart" cell therapies that use gene circuits to more precisely target cancer cells. This chart reflects revenue from strategic partnerships. It illustrates the financial support for this cutting-edge approach that programs cells to perform complex therapeutic functions.
Sales of companies in the market segment - Oncology cell gene therapy
Senti Biosciences, Inc. is a biotechnology company developing next-generation cell and gene therapies using gene circuit technology for the treatment of cancer and other diseases. Its activities are segmented into various development programs. This chart reflects the financial flows associated with one of its key oncology areas.
Overall market sales
Senti Biosciences, Inc. is a biotechnology company using synthetic biology to create "smart" cell therapies. Its circuit cells can be programmed to perform complex functions, such as targeting only cancer cells. This is cutting-edge science that could lead to the creation of highly precise and safe next-generation drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Senti Biosciences Inc.
Senti Biosciences is a biotech company developing "smart" cell and gene therapies using genetic blueprints that enable drugs to make logical decisions. Future sales projections are a bet that its cutting-edge platform will enable the creation of more precise and safer treatments for cancer and other serious diseases.
%20sales%20of%20the%20company%20Senti%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Senti-Biosciences-Inc.&v=1772513651686 "Schedule of future (projected) sales of the company Senti Biosciences Inc.")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Senti Biosciences develops "smart" cell and gene therapies using gene-mapping technology for more precise cancer treatment. This chart shows expectations for the cell therapy sector. It helps assess the progress being made in creating programmable drugs and the commercial potential analysts predict for this cutting-edge field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772513651729 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Senti Biosciences, a company using synthetic biology to create smart cell therapies, is funding its products entirely on investors' faith in the breakthrough potential of its technology. This chart of total sales forecasts reflects the market's risk appetite required to support such cutting-edge startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513651822 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Senti Biosciences Inc.
Senti Biosciences, Inc. is a biotechnology company developing next-generation cell and gene therapies using gene circuit technology for more precise cancer treatment. This chart shows its financial status at the R&D stage, where significant investments in a sophisticated scientific platform are the foundation for future therapeutic breakthroughs.
Market segment marginality - Oncology cell gene therapy
Senti Biosciences is a biotech company developing smart cell therapies that can be programmed to perform complex functions in the body. The effectiveness of their genetic engineering platform is key to creating a new generation of drugs. The graph shows their operating costs for this research-intensive process.
Market marginality as a whole
Senti Biosciences, Inc. is a biotechnology company developing "smart" cell and gene therapies that can be programmed to perform complex functions in the body. It is at the forefront of synthetic biology. This chart shows the profitability of established companies, but for SNTI, success depends on breakthroughs in its technology and the creation of a new generation of drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Senti Biosciences Inc.
Senti Biosciences develops "smart" cell and gene therapies using gene circuit technology. This graph shows the team of innovative scientists. The size of this team reflects the scale of investment in creating the next generation of drugs that can more precisely target disease and control their activity.
Share of the company's employees Senti Biosciences Inc. within the market segment - Oncology cell gene therapy
Senti Biosciences develops "smart" cell therapies that can be programmed to perform complex functions in the body. This cutting-edge field of synthetic biology requires an elite team of scientists. This statistic reflects its leadership and depth in the development of next-generation drugs.
Number of employees in the market segment - Oncology cell gene therapy
Senti Biosciences develops "smart" cell and gene therapies using genetic circuits that allow the drug to act only under specific conditions. This chart reflects employment in this cutting-edge sector. The growing number of synthetic biologists indicates a shift toward programmable drug development, which is the core of Senti's innovative approach.
Number of employees in the market as a whole
Senti Biosciences is developing next-generation gene therapies. It's at the cutting edge of science, where innovation is king. This graph reflects the current labor market, but Senti is hiring exceptional talent to create smart drugs, and its growth depends on investment in its revolutionary platform.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Senti Biosciences Inc. (SNTI)
Senti Biosciences, Inc. is a biotechnology company developing smart cell therapies using gene circuits. It is at the forefront of synthetic biology. The enormous market capitalization per employee in this chart reflects investors' faith in the revolutionary potential of this technology created by an elite team of scientists.
%20of%20the%20company%20Senti%20Biosciences%20Inc.%20(SNTI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Senti-Biosciences-Inc.-SNTI&v=1772513652009 "Chart of market capitalization per employee (in thousands of dollars) of the company Senti Biosciences Inc. (SNTI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Senti Biosciences is developing a new generation of cell and gene therapies using gene circuit technology. In advanced synthetic biology, this metric reflects how highly the market values their breakthrough scientific platform. It's a measure of investor confidence in the team's ability to create "smart" drugs.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772513652021 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Senti Biosciences, Inc. is a biotechnology company developing next-generation cell and gene therapies that can be programmed as "smart" drugs to perform complex functions in the body. The chart shows the high premium the market commands for its cutting-edge synthetic biology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513652058 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Senti Biosciences Inc. (SNTI)
Senti Biosciences is a biotech company developing "smart" cell and gene therapies. They use "gene circuits" to program cells to attack cancer or treat diseases. It's an R&D platform. This graph (negative) shows how much capital is invested in each scientist working on this futuristic, but highly complex and expensive technology.
%20Chart%20Senti%20Biosciences%20Inc.%20(SNTI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Senti-Biosciences-Inc.-SNTI&v=1772513652127 "Company Profit Per Employee (in thousands of dollars) Chart Senti Biosciences Inc. (SNTI)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company using synthetic biology to create "smart" cell therapies that can make decisions within the body. This cutting-edge science requires unique specialists. This graph shows how productive their team is in creating future technologies, compared to other innovative biotech companies.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772513652250 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Senti Biosciences (SNTI) is a biotech company developing smart cell therapy (gene circuit). It's a clinical-stage R&D company. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on this complex technological platform, which is not yet generating revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513652360 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Senti Biosciences Inc. (SNTI)
Senti Biosciences is a biotechnology company developing next-generation cell and gene therapies using gene circuits. It has no sales revenue at the preclinical stage. This timeline will show whether its complex scientific platform can lead to commercial products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Senti-Biosciences-Inc.-SNTI&v=1772513652439 "Sales chart per company employee Senti Biosciences Inc. (SNTI)")
Sales per employee in the market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company using gene-based technology (synthetic biology) to create smart cell therapies for cancer treatment. This chart compares their revenue per employee (R&D) to the industry average, reflecting how productive their advanced and sophisticated scientific platform is on the path to commercialization.
Sales per employee for the market as a whole
Senti Biosciences (SNTI) is a biotech company developing smart cell therapy (CAR-NK) using genetic engineering. They program cells to treat cancer. They are a clinical-stage R&D company with no commercial sales revenue. This graph will reflect $0, as their research staff is focused on research.
Short shares by company, segment and market as a whole
Shares shorted by company Senti Biosciences Inc. (SNTI)
Senti Biosciences (SNTI) is a biotech company developing "smart" cell therapies. They are attempting to "program" cells to attack cancer more precisely. This is cutting-edge, but still very early and speculative science. This chart shows the number of investors who believe this technology is overly complex and far from reality.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Senti-Biosciences-Inc.-SNTI&v=1772513652715 "Short Shares Chart for the Company Senti Biosciences Inc. (SNTI)")
Shares shorted by market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing "smart" cell therapies. They use genetic engineering to create cells that can make decisions, such as attacking only cancer cells while ignoring healthy ones. This chart shows the odds against the "synthetic biology" sector, reflecting the market's skepticism about this highly complex technology.
Shares shorted by the overall market
Senti Biosciences "programs" cells for gene therapy. This is cutting-edge science. This chart reflects the overwhelming market pessimism. For investors, it looks like a scientific project with an uncertain outcome. During times of fear, capital flees such complex and "long-term" projects in favor of clear and profitable businesses.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Senti Biosciences Inc. (SNTI)
Senti Biosciences is a biotech company developing "smart" cell therapies (gene circuits) designed to more precisely attack cancer. This is very early and complex science. This chart tracks investor hype, showing "overheated" (above 70) due to faith in the technology or "oversold" (below 30) due to slow progress in trials.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Senti-Biosciences-Inc.-SNTI&v=1772513652899 "RSI 14 indicator chart for the company's stock Senti Biosciences Inc. (SNTI)")
RSI 14 Market Segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing "smart" cell therapies. Their approach uses "gene circuits" to train immune cells to more precisely attack cancer. This chart shows the overall "temperature" in the volatile gene and cell therapy sector. It helps separate SNTI's dynamics from the general "hype" or "disappointment" that has engulfed this entire biotech niche.
RSI 14 for the overall market
Senti Biosciences (SNTI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SNTI (Senti Biosciences Inc.)
Senti Biosciences is a biotech company developing a smart cell therapy (Logic Gated) for cancer treatment that can accurately distinguish between diseased and healthy cells. This chart shows the average target price. Analysts' forecasts are based on an assessment of the potential of this advanced platform and data from early trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SNTI-Senti-Biosciences-Inc.&v=1772513653151 "A chart showing analyst consensus forecasts for the expected stock price. SNTI (Senti Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price SNTI (Senti Biosciences Inc.)
Senti Biosciences is a biotech company that "programs" cells. Their platform (gene circuits) enables the creation of "smart" cell therapies that work only where needed. This chart shows how much the current stock price differs from the "fair" value predicted by analysts. It reflects their faith in this complex science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SNTI-Senti-Biosciences-Inc.&v=1772513653180 "A chart showing the difference between the consensus forecast and the actual stock price. SNTI (Senti Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Senti Biosciences is a biotech company developing "smart" cell therapies (CAR-NK). It uses "gene blueprints" to program cells to attack only cancer. This chart shows general expectations for the oncology sector. It reflects whether experts believe in the future of "programmable" medicine.
Analysts' consensus forecast for the overall market share price
Senti Biosciences is a biotech company developing "gene blueprints" (like computer code) to create "smart" cell therapies (NK cells) that can make decisions within the body. This chart shows the overall "risk appetite" in the market. For Senti, working in one of the most advanced and risky areas of medicine, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Senti Biosciences Inc.
Senti Biosciences are cellular programmers. They're a next-generation biotech company that uses synthetic biology to create smart cell therapies (NK cells) that can be turned on and off (like a computer). This chart is a clear indicator of their faith in their deep science, reflecting their (highly risky) R&D progress.
AKIMA Market Segment Index - Oncology cell gene therapy
Senti Biosciences (SNTI) is a genetic engineering company that programs cell and gene therapies. They use genetic engineering to create smarter drugs that target specific cancer cells. The chart shows the segment average, helping investors assess how this cutting-edge technology compares to the sector average.
The AKIM Index for the overall market
Senti Biosciences is a biotech company that creates "gene blueprints" for programming cell and gene therapies. It makes treatments smarter. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this cutting-edge synthetic biology company.
